Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2012 | short review

The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer

verfasst von: Zoltán Lőcsei, MD, Katalin Hideghéty, MD, PhD, Dr. habil. Zsuzsanna Kahán, MD, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

PET or PET/CT mostly utilizing the tracer [18F]fluorodeoxyglucose (18FDG) are unique imaging methods for the detection of breast cancers with increased glucolytic activity. PET/CT simultaneously provides anatomic and metabolic information by detecting increased glucose uptake. PET/CT may provide extra information on stage that can be utilized in certain cases during treatment decision making. PET/CT is a very sensitive imaging option to detect lymph node involvement or distant metastasis for which information is needed in selected cases. In the neoadjuvant or metastatic setting, PET or PET/CT may serve as a valuable noninvasive option for investigating chemosensitivity and monitoring the effectiveness of systemic therapy. Its use, however, should be reserved for particular cases with diagnostic uncertainty in the routine management of breast cancer.
Molecular imaging with non-FDG PET tracers developed using advanced molecular and cell biology techniques widens the possibility to study the pathological molecular events and processes in breast cancer, and may be used for the detection of key molecules to be targeted by pharmaceutical interventions; the method provides new possibility to evaluate novel drugs.
Vorheriger Artikel Surgical removal of the primary?—The role it plays in stage IV breast cancer
Nächster Artikel Breast cancer: is there a need for biopsy of metastases?
Literatur
1.
Makhoul I, Kiwan E. Neoadjuvant systemic treatment of breast cancer. J Surg Oncol. 2011 Mar 15;103(4):348–57.CrossRefPubMed
2.
Robertson IJ, Hard F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011 Jul 30. Epub ahead of print.
3.
Monzawa S, Adachi S, Suzuki K, et al. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastases: comparison with ultrasonography and contrast-enhanced CT. Ann Nucl MED. 2009;23(10):855–61.CrossRefPubMed
4.
Ueda S, Tsuda H, Asakawa H, et al. Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer. 2008;8:165CrossRefPubMed
5.
Fuster D, Duch J, Paredes P, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol. 2008;26:4746–51.CrossRefPubMed
6.
Carkaci S, Macapinlac HA, Cristofanilli M, et al. Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data. J Nucl Med. 2009;50(2):231–8.CrossRefPubMed
7.
Alberini JL, Lerebours F, Wartski M, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer. 2009 Nov 1;115(21):5038–47.CrossRefPubMed
8.
Groheux D, Moretti JL, Baillet G, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):695–704.CrossRefPubMed
9.
Groheux D, Giacchetti S, Espié M, et al. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med. 2011;52:1526–34.CrossRefPubMed
10.
Koolen BB, Vegt E, Rutgers EJ, Vogel WV, et al. FDG-avid sclerotic bone metastases in breast cancer patients: a PET/CT case series. Ann Nucl Med. 2011 Sept 28. Epub ahead of print.
11.
Hahn S, Heusner T, Kümmel S, et al. Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer. Acta Radiol. 2011 Nov 1;52(9):1009–14.CrossRefPubMed
12.
Niikiura N, Costelloe CM, Madewell JE, et al. FDG-PET/CT compered with conventional imaging in the detection of distant metastases of primary breast cancer. Oncologist. 2011;16(8):1111–9.CrossRef
13.
Ohsumi S, Inoue T, Kiyoto S, et al. Detection of isolated ipsilateral regional lymph node recurrences by F18-fluorodeoxyglucose positron emission tomography-CT in follow up of postoperatve brast cancer patients. Breast Cancer Res Treat. 2011. Epub ahead of print.
14.
Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG-PET/CT) in primary breast cancer. J Clin Oncol. 2008;38(4):250–8.
15.
Ueda S, Tsuda H, Saeki T, et al. Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer. Breast J. 2010;16(6):660–2.CrossRefPubMed
16.
Ueda S, Tsuda H, Saeki T, et al. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. 2011;18(4):299–308.CrossRefPubMed
17.
Wang CL, MacDonald LR, Rogers JV, et al. Positron emission mammography: correlation of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status and 18F-FDG. AJR Am J Roentgenol. 2011;197(2):W247–55.CrossRefPubMed
18.
Ueda S, Saeki T, Shigekawa T, et al. (18)F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response. Int J Clin Oncol. 2011 Aug 10. Epub ahead of print.
19.
Keam B, Im SA, Koh Y, et al. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011 Oct 20;11:452.CrossRefPubMed
20.
Kumar A, Kumar R, Seenu V, et al. The role of (18)F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol. 2009;19:1347–57.CrossRefPubMed
21.
Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2007,34:1915–24.CrossRefPubMed
22.
Duch J, Fuster D, Munoz M, et al. (18)F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2009;36:1551–7.CrossRefPubMed
23.
Dunnwald LK, Gralow JR, Ellis GK, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 2008;26:4449–57.CrossRefPubMed
24.
Jung SY, Kim SK, Nam BH, et al. Prognostic impact of [(18)F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2009;17:247–53.CrossRefPubMed
25.
Rousseau C, Devillers A, Sagan C, et al. Monitoring of early response to neoadjuvant chemotherapy in stage ii and iii breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol. 2006;24:5366–72.CrossRefPubMed
26.
Schwarz-Dose J, Untch M, Tiling R, et al. Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2009;27:535–41.CrossRefPubMed
27.
Padmanabhan P, Goggi J, Bejot R, et al. Molecular targeting of breast cancer: imaging and therapy. Curr Pharm Biotechnol. 2011;12(4):528–38.CrossRefPubMed
28.
Sekar TV, Dhanabalan A, Paulmurugan R, et al. Imaging cellular receptors in breast cancers: an overview. Curr Pharm Biotechnol. 2011;12(4):508–27.CrossRefPubMed
29.
Tomasi G, Kenny L, Mauri F, et al. Quantification of receptor-ligand binding with [(18)F]fluciclatide in metastatic breast cancer patients. Eur J Nucl Med Mol Imaging. 2011;38(12):2186–97.CrossRefPubMed
30.
Hatt M, Cheze-Le Rest C, Aboagye EO, et al. Reproducibility of 18F-FDG and 3′-deoxy-3′-18F-fluorothymidine PET tumor volume measurements. J Nucl Med. 2010;51(9):1368–76.CrossRefPubMed
31.
Krause BJ, Schwarzenböck S, Schwaiger M. Tracers in oncology—preclinical and clinical evaluation. Nuklearmedizin. 2010;49(Suppl 1):S41–5.PubMed
32.
33.
Contractor KB, Kenny LM, Stebbing J, et al. [11C]choline positron emission tomography in estrogen receptor-positive breast cancer. Clin Cancer Res. 2009 Sept 1;15(17):5503–10.CrossRefPubMed
34.
Contractor KB, Kenny LM, Stebbing J, et al. Biological basis of (11C)choline-positron emission tomography in patients with breastcancer: comparison with (18F)fluorothymidine positron emission tomography. Nucl Med Commun. 2011;32(11):997–1004.CrossRefPubMed
35.
Oude Munnink TH, Nagengast WB, Brouwers AH, et al. Molecular imaging of breast cancer. Breast. 2009;18(Suppl 3):S66–73.CrossRefPubMed
36.
Linden HM, Kurland BF, Peterson LM, et al. Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res. 2011 Jul 15;17(14):4799–805.CrossRefPubMed
37.
Kurland BF, Peterson LM, Lee JH, et al. Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET. J Nucl Med. 2011;52(10):1541–9.CrossRefPubMed
38.
Tinianow JN, Gill HS, Ogasawara A, et al. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. Nucl Med Biol. 2010;37(3):289–97.CrossRefPubMed
39.
Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastaticbreast cancer. Clin Pharmacol Ther. 2010;87(5):586–92.CrossRefPubMed
40.
Manning K, Tepfer B, Goldklang G, et al. Clinical practice guidelines for the utilization of positron emission tomography/computed tomography imaging in selected oncologic applications: suggestions from a provider group. Mol Imaging Biol. 2007;9(6):324–32.CrossRefPubMed
Metadaten
Titel
The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer
verfasst von
Zoltán Lőcsei, MD
Katalin Hideghéty, MD, PhD
Dr. habil. Zsuzsanna Kahán, MD, PhD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0007-2

Weitere Artikel der Ausgabe 2/2012

Immunotherapeutic approaches targeting prostate cancer and its microenvironment

  • short review

Clinical practice guidelines in oncology—achievements and challenges

  • editorial

Breast cancer: is there a need for biopsy of metastases?

  • short review

Immunotherapy for nonsmall-cell lung cancer

  • short review

Sjögren syndrome complicated with hairy-cell leukemia: a case-based review

  • case report

Is distinct EGFR mutation status proof of second simultaneous primary non-small cell lung cancer?

  • case report